The North America cancer metabolism based therapeutics market, valued at USD 1.32 billion in 2025, is projected to reach USD 1.78 billion in 2026 and USD 12.03 billion by 2035, with a CAGR of 23.7% during the forecast period 2026 to 2035. North America continues to report a substantial oncology disease burden, creating sustained demand for therapies that can address difficult-to-treat and genetically defined cancers. In the US alone, around 2.11 million new cancer cases and 626,140 cancer deaths...

The global RNAi therapeutics and technology market, valued at USD 6.2 billion in 2025, is projected to reach USD 7.4 billion in 2026 and USD 21.6 billion by 2035, representing a CAGR of 12.6% during the forecast period 2026 to 2035. In June 2026, Arrowhead Pharmaceuticals received European Commission marketing authorization for REDEMPLO® (plozasiran), a small interfering RNA medicine for adults with familial chylomicronemia syndrome. In June 2026, AviadoBio expanded its exclusive license for th...

The North America liquid biopsy market, valued at USD 4.5 billion in 2025, is projected to reach USD 5.2 billion in 2026 and USD 17.4 billion by 2035, representing a CAGR of 14.4% during the forecast period 2026 to 2035. Tissue biopsy has historically served as the standard approach for cancer diagnosis and molecular profiling, as it allows clinicians to directly examine tumor tissue and identify disease-specific characteristics. However, its invasive nature often creates challenges for patients...

The global Crohn’s disease market size, valued at USD 9.6 billion in 2025, is projected to reach USD 10.3 billion in 2026 and USD 18.1 billion by 2035, representing a CAGR of 6.5% during the forecast period 2026 to 2035. Based on the route of administration, the subcutaneous route dominates (more than 40%) the future market (2035). The rising prevalence of Crohn’s disease represents a major market opportunity within this domain. Notably, in 2023, an estimated 1 million patients were living w...

The global ulcerative colitis market size, valued at USD 13.0 billion in 2025, is projected to reach USD 14.0 billion in 2026 and USD 25.7 billion by 2035, representing a CAGR of 7.0% during the forecast period 2026 to 2035. Based on route of administration, the subcutaneous route dominates (more than 40%) the current market; this trend is unlikely to change in the future. With respect to distribution channels, hospital pharmacies are expected to capture most of the future ulcerative colitis mar...

The global bacteriophage therapy market, valued at USD 58.1 million in 2025, is projected to reach USD 66.5 million in 2026 and USD 266.8 million by 2035, representing a CAGR of 16.7% during the forecast period 2026 to 2035. In terms of target indication, urinary tract infections hold the highest (around 30%) share of the current market. With respect to route of administration, oral route dominates the current market.

The global idiopathic short stature market is expected to rise from USD 1.85 billion in 2026 to reach USD 5.08 billion by 2040, growing at a CAGR of 7.48% over the forecast period 2026 to 2040, driven by weekly growth hormone adoption, home-based treatment, and genetic reclassification of short stature. Based on Geography, North America captures 45.0% market share in 2026, whereas Asia-Pacific registers a 10.2% CAGR through 2040, driven by faster private endocrine care expansion. Based on Therap...

The Europe cancer metabolism based therapeutics market, valued at USD 0.82 billion in 2025, is projected to reach USD 1.12 billion in 2026 and USD 8.54 billion by 2035, with a CAGR of 25.3% during the forecast period 2026 to 2035. In terms of type of modality, small molecules are expected to account for the largest market share in 2026; this trend is unlikely to change in the future. With respect to route of administration, oral route (close to 85%) is expected to dominate the market in 2035. Th...

The global RNAi therapeutics market, valued at USD 2.9 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 9.1 billion by 2035, representing a CAGR of 10.8% during the forecast period 2026 to 2035. With respect to route of administration, intravenous administration accounts for the highest share, capturing 45% of the current market. In June 2026, Alnylam Pharmaceuticals and Inceptive Nucleics announced a strategic AI-driven collaboration valued at up to USD 2 billion, includin...

The global Duchenne muscular dystrophy market reached USD 5.2 billion in 2026 and is projected to reach USD 28.7 billion by 2040, growing at a CAGR of 13.0% over the forecast period 2026 to 2040, driven by mutation-targeted therapies, gene transfer adoption, and broader rare-disease reimbursement. Based on therapy class, gene therapies capture 34.0% market share in 2026, whereas cell therapies register a 28.4% CAGR through 2040, driven by late-stage cardiac and skeletal-muscle programs. Based on...

The North America non-viral transfection reagents market, valued at USD 0.31 billion in 2025, is projected to reach USD 0.34 billion in 2026 and USD 0.70 billion by 2035, representing a CAGR of 8.5% during the forecast period 2026 to 2035. Non-viral transfection reagents have become integral to modern molecular biology and therapeutic development, offering reliable and scalable alternatives to viral vectors for delivering nucleic acids into cells. The chemical and physical transfection approache...

The global PERK inhibitors market is envisaged to rise from USD 46.0 million in 2026 and is projected to reach USD 450.0 million by 2040, growing at a CAGR of 17.7% over the forecast period 2026 to 2040, driven by Phase 1b oncology combination development and research-enablement demand. Based on product / offering type, therapeutic drug candidates is both the dominant and fastest-growing category, holding 34.0% share in 2026 and expanding at 21.3% CAGR through 2040, driven by oncology pipeline v...

The global CRISPR based therapeutics market, valued at USD 0.1 billion in 2025, is projected to reach USD 0.2 billion in 2026 and USD 6.3 billion by 2035, with a CAGR of 43.8% during the forecast period 2026 to 2035. The CRISPR domain has evolved from basic scientific research into an important area of advanced therapeutics. Notably, the in vivo therapies segment is expected to grow at a significant pace during the forecast period due to rapid advancements in targeted gene-editing delivery techn...

The Europe non-viral transfection reagents market, valued at USD 0.22 billion in 2025, is projected to reach USD 0.24 billion in 2026 and USD 0.40 billion by 2035, representing a CAGR of 5.7% during the forecast period 2026-2035. Non-viral transfection reagents refer to chemical or physical delivery systems that introduce nucleic acids, including DNA, RNA, mRNA, siRNA, and gene editing components, into target cells without relying on viral vectors. In addition, rising investment in nucleic acid-...

The global RNAi technology market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.8 billion in 2026 and USD 12.5 billion by 2035, representing a CAGR of 14.0% during the forecast period 2026 to 2035. RNA interference (RNAi) technology is a gene-silencing approach that selectively suppresses disease-causing genes at the messenger RNA (mRNA) level. Initially developed as a research tool, RNAi has evolved into a clinically validated therapeutic platform. Currently, the siRNA segment...

The global cell therapy manufacturing market, valued at USD 6.3 billion in 2025, is projected to reach USD 7.2 billion in 2026 and USD 14.0 billion by 2035, representing a CAGR of 7.7% during the forecast period 2026 to 2035. Researchers are investigating more than 1,000 cell and gene therapy candidates for the treatment of a myriad of disease indications. Amongst these, around 45 cell-based therapies have already been approved by various regulatory authorities across the globe. Further, several...

The global CAR-T cell therapy market, valued at USD 6.1 billion in 2025, is projected to reach USD 7.7 billion in 2026 and USD 15.6 billion by 2035, with a 8.1% CAGR during the forecast period 2026 to 2035. In terms of target antigen, the CD19 targeting therapies segment holds the highest share (more than 65%) of the market. With regards to target indication, the multiple myeloma segment dominates the global market with close to 30% market share. In terms of geographical regions, North America c...

The global contact lenses market, valued at USD 12.7 billion in 2025, is projected to reach USD 13.2 billion in 2026 and USD 20.5 billion by 2035, representing a CAGR of 5.0% during the forecast period 2026 to 2035. Contact lenses are thin, transparent optical devices placed directly on the cornea to correct refractive errors, and are currently worn by approximately 150 million individuals worldwide. In fact, in the US alone, an estimated 45 million people use contact lenses, with 87% opting fo...

The global Fc fusion protein market, valued at USD 40.7 billion in 2025, is projected to reach USD 45.0 billion in 2026 and USD 103.7 billion by 2035, representing a CAGR of 9.7% during the forecast period 2026 to 2035. In terms of type of fusion molecule, receptor ECD segment holds the highest share of the current market. In March 2026, Shanghai Henlius Biotech dosed the first patient in a Phase 1b/2 trial of HLX701, a next-generation SIRPα-Fc fusion protein, in combination with cetuximab and...

The E. coli fermentation market, valued at USD 7.8 billion in 2025, is projected to reach USD 8.6 billion in 2026 and USD 17.3 billion by 2035, representing a CAGR of 8.2% during the forecast period 2026 to 2035.Driven by the preference of major drug developers to retain end-to-end control over their proprietary microbial expression strains and quality control, the in-house manufacturers (~70%) dominate the E. coli fermentation market. In April 2026, WuXi Biologics achieved structural completion...